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Summary The prognostic value of flow cytometric parameters and tumour growth rate of melanoma
metastases under the mouse renal capsule was investigated for tumours from 117 consecutive patients referred
to the Helsinki University Central Hospital Melanoma Team. DNA flow cytometry (FCM) was interpretable
for the tumours of 114 patients, and growth rate analysis for 82 patients, both results being available from 79
patients. Thirty-six percent of the tumours were DNA diploid and 64% DNA aneuploid. Tumour ploidy and
S-phase fraction were shown by multivariate Cox model analysis to be independent prognostic variables and
major determinants of survival after first recurrence. Patients with DNA diploid or aneuploid tumours
survived a median 16 and 27 months, respectively. A high growth rate of tumour sample in vivo under the
mouse renal capsule tended to be a sign of poor prognosis, although not reaching statistical significance.
Combining the results of FCM, tumour growth rate and TNM stage, we propose a highly efficient prognostic
scoring method. Patients with a score above 0.75 had a median survival of 11 months compared to 30 months
among patients scoring under 0.75 (P<0.0001). This score was the most significant (P<0.0001) prognostic
factor in the Cox model when TNM stage, age, ploidy, SPF, and tumour growth rate were analysed as
covariates.
Malignant melanoma is known for its varying clinical course
and its resistance to most non-surgical therapeutic approa-
ches. A few parameters, such as the number of metastatic
lymph nodes and the sites of metastases, are known to
predict the clinical behaviour of advanced melanoma (Balch
et al., 1985).
Flow cytometric analysis of nuclear DNA content and
S-phase fraction (SPF) is a feasible method of estimating the
malignant potential and growth characteristics of variable
malignant tumours (Seckinger et al., 1989). In many tumours
DNA aneuploidy and high S-phase fraction (SPF) are report-
ed to correlate with poor prognosis. DNA aneuploid primary
melanomas recur earlier and more frequently than do DNA
diploid melanomas (Buchner et al., 1985; Frankfurt et al.,
1984; Gattuso et al., 1990; Kheir et al., 1988; Lindholm et
al., 1989; S0ndergaard et al., 1983; von Roenn et al., 1986).
DNA aneuploidy has also been associated with shorter sur-
vival in primary melanoma (Bartkowiak et al., 1991; Lind-
holm, 1989; S0ndergaard et al., 1983). Patients with DNA
aneuploid mestastatic melanoma have also had, according to
one report, worse prognosis than did patients with DNA
diploid tumours (S0ndergaard et al., 1983), while another
study showed no association of DNA ploidy but only of the
S-phase fraction with prognosis (Hansson et al., 1982). In
our own study we found that in contrast to earlier reports
DNA aneuploidy correlated with favourable prognosis
(Muhonen et al., 1991).
The mouse subrenal capsule assay (SRCA) originally des-
cribed by Bogden et al. (1981; 1978) has been used as an
experimental tool to screen efficacy of antineoplastic drugs.
However, change in tumour size under the renal capsule of
saline-treated mice can also give an estimate of the growth
rate and thus of the aggressiveness of the tumour.
We have correlated the tumour growth rate under the
mouse renal capsule as well as flow-cytometrically-determin-
ed DNA ploidy and S-phase fraction with the clinical out-
come of patients with metastatic melanoma.
Materials and methods
Patients
The group studied consisted of 117 consecutive patients (68
male, 49 female) with metastatic melanoma treated and sub-
sequently followed up at the Department of Plastic Surgery
and at the Department of Radiotherapy and Oncology of
Helsinki University Central Hospital between August 1983
and June 1991. Tumour specimens were obtained when
regional or distant metastases were found. The major charac-
teristics of the patients are presented in Table I.
Tumour samples
Fresh tumour samples from 117 patients were analysed. The
specimens for growth rate testing were cut into 3-4 mm
Table I Patient characteristics
Total no. ofpatients 117
No. of patients with SRCA
No. of patients with FCM
No. of patients with both SRCA and FCM
available
Male/female
Mean age (range)
Stage at recurrencea
III, lymph node involvement
IV
82
114
79
68/49
54 (25-84)
58
59
Status at end of follow up (median follow up time)
Alive 38 (31 months)
Deceased 79 (15 months)
Sites of biopsies
Lymph nodes 72
Cutaneous or subcutaneous 33
Lung 3
Other 9
aIncluding eight patients with metastatic disease at the primary
admission to clinic.
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pieces and transferred to a cell-culture medium for transport
at a room temperature to the Farmos cancer research labora-
tory, Turku, Finland. Medium 199 (KC Biological, Lenexa,
Ks, USA) supplemented with antibiotics (penicillin + strepto-
mycin or gentamycin) was used in all phases of tumour
handling. Implantation of the tumour was accomplished
within 24 h. This procedure was adopted on the basis of the
experience of the Farmos laboratory (Miienpiaa, 1985) as well
as that of others (Slagel et al., 1985). A total of 3708
implants of 103 tumours obtained from 82 melanoma
patients were analysed.
The samples for flow cytometric DNA analysis were
immediately frozen in liquid nitrogen and stored thereafter at
-80°C until analysed. DNA analysis was interpretable for 72
individuals of the whole growth-rate tested group. All the
specimens were confirmed as representing melanoma by
examining the adjacent sections histologically.
Tumour growth rate under mouse renal capsule
The method of implanting human tumours under the kidney
capsule of mice has been described by Bogden et al. (1981).
Normal immunocompetent BDF1 and CDF1 hybrid mice
provided by the Laboratory Animal Center, Kuopio, Fin-
land, or Alab, Sollentuna, Sweden, and weighing 20-30g,
were used as recipients. Briefly, the mice were anaesthetised
with chloral hydrate (370mgkg-' i.p.), the left kidney was
partially exteriorised and one or two 1 mm3 tumour frag-
ments were implanted under the capsule. The size of the
implant was determined in situ by a stereomicroscope fitted
with an ocular micrometer. The change in tumour size (Ats)
as ocular microscopic units (omu) was calculated as the
difference between the final and initial tumour sizes. The
initial and final body weight were measured to evaluate
toxicity. For 13 patients, more than one tumour sample was
analysed. Only the results of the primary assay are used in
this analysis. The assays were carried out in four separate
subsequent series. Since each of the series showed a different
level of change in tumour size (Ats), a straightforward com-
parison of the results was not possible. Thus a new para-
meter: relative growth rate was calculated:
observed individual
Relative growth rate change in tumour size (Ats) * 100% median change in tumour
size (Ats) of the series
Flow cytometric analysis
For analysis the tumour samples were rapidly thawed in a
37°C water bath and processed immediately by scalpel and
scissors into single cell suspensions. Each cell suspension was
filtered through a 50gm nylon mesh. The filtrate was centri-
fuged for 5 min at 1600 r.p.m. Chicken and trout red blood
cells were added as internal standards (Vindel0v et al., 1983).
The pellet was resuspended by adding 0.5 ml of ethidium
bromide (50 tg ml1' in 10 mM Tris buffer, I mM EDTA,
0.3% Nonident P40, pH 7.5). The tube was vortexed and
held on ice for 15 min. Then 0.25 ml of a solution containing
1 mgml-' RNAse (Sigma) was added to the tube, which was
incubated for 15 min at room temperature. Immediately
before analysis the sample was filtered through a 30 jm
nylon mesh. Ten samples were prepared from paraffin-
embedded material according to the procedure described
previously (Kouri et al., 1990). Routinely at least 15,000 cells
per sample were analysed using an EPICS C flow cytometer
(Coulter, Hialeah, Florida). A 2 W argon ion laser was used
for excitation at a wavelength of 488 nm, and the total
emission above 590 nm was measured.
The flow cytometric parameters evaluated included the
DNA ploidy and DNA index (DI, where DI represents the
ratio of the aneuploid stem line GI DNA peak channel to
the diploid stem line G1-DNA peak channel). Tumours were
classified as aneuploid if there occurred a second GI-peak in
addition to the diploid GI-peak. Aneuploid tumours with a
DI between 1.9 and 2.1 and a definable S- and G2M-phase
were defined as tetraploid. The S-phase fraction (SPF) was
calculated as described previously (Pyrhonen et al., 1991).
When multiple samples per patient were available the average
SPF value was used, and the DNA ploidy of the patient was
coded as the most deviant DNA ploidy among those sam-
ples. Samples with a coefficient of variation greater than
8.0% or with a large amount of debris or with near diploid
aneuploidy were excluded from the cell cycle analysis. Since
the distribution of SPF values differed significantly between
DNA diploid and aneuploid tumours, a new parameter, SPF
index, was calculated, dividing the SPF values into two
groups based on whether the individual patients' SPF was
over or under the median SPF of his DNA ploidy group.
Statistical methods
Differences between mean values were analysed using Stu-
dent's t-test, and differences between frequencies using the
method of contingency tables.
For calculation of survival after metastases, product-limit
survival analysis was performed using the BMDP IL com-
puter program (Dixon, 1988). Brookmeyer-Crawley 95%
confidence limits for median survival time are reported. Cal-
culations of the significance of observed differences were
performed using the log rank test (Mantel-Cox). P-values
under 0.05 were considered statistically significant. Cox
multivariate analysis was performed with the BMDP 2L
computer program using DNA ploidy, SPF index, relative
growth rate under the renal capsule, TNM stage, sex, age,
disease-free survival and tumour pigmenation as covariates.
Results
Tumour growth rate under mouse renal capsule and DNAflow
cytometry
The median change in tumour size, Ats (range) was 1.1 omu
(-0.9-8.3) in the first series (n = 20), 1.6 omu (0.3-10.2) in
the second series (n = 38), 2.9 omu (1.0-8.3) in the third
series (n = 16) and 7.2 omu (2.5-13.8) in the final series
(n = 7).
A single diploid clone was detected in 41 patients, while 50
other patients exhibited a single aneuploid clone in addition
to the diploid one. A further eight patients had a tetraploid
clone, and 15 showed multiple aneuploid clones.
The S-phase fraction was calculable for 91 patients. The
DNA diploid tumours (n = 39) showed a significantly (P =
0.0001) lower SPF than did DNA aneuploid ones (n = 52),
median 10.1 and 16.8 respectively.
The median growth rates of DNA diploid and DNA aneu-
ploid tumours were 2.0Omu (-0.05-13.8) and 2.2 (-0.9-
10.2), respectively. The difference is not statistically significant,
nor was correlation detected between SPF value and growth
rates.
Tumour growth rate under mouse renal capsule andsurvival
after metastases
Patients with rapidly growing tumour specimens tended to
have less favourable prognosis. Median survival after metas-
tases of patients whose tumour growth rate exceeded the
median of its series was 22 months (95% confidence 15-35)
compared to 31 months (95% confidence 25-39) among
patients with slowly growing tumours (Figure 1). This differ-
ence does not, however, reach the level of significance
(P> 0.05, log-rank test).
FCM results and survival after metastases
DNA aneuploidy was associated with favourable prognosis.
Median survival of patients with DNA diploid metastases
was 16 months (95% confidence 13-25) compared to 27
months (95% confidence 23-36) for patients with aneuploid
metastases; the difference is not, however, significant (P>530 T. MUHONEN et al.
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Figure 1 Cumulative proportion of melanoma patients surviving after the appearance of first metastases. a, Patients with tumours
growing slowly under the mouse renal capsule (---, n = 41) having better survival than those with rapidly growing tumours (-O-,
n = 41) (P>0.05, product limit, Mantel-Cox). b, Patients with DNA aneuploid tumours (-U-, n = 73) having better survival than
those with DNA diploid tumours (-O-, n = 41) (P>0.05, product limit, Mantel-Cox). c, Patients with SPF below or at the median
(---, n = 46) showing significantly better prognosis than patients with SPF above median (-O-, n = 45) (P<0.002, product limit,
Mantel-Cox). d, TNM stage III patients (-U-, n = 58) showing significantly better prognosis than patients with stage IV disease
(-O-, n = 59) (P<0.01, product limit, Mantel-Cox, P>0.05 in multivariate analysis with SPF index, ploidy and relative growth
rate as covariates). e, Patients with prognostic four-variable score at or above 0.75 (-A-, n = 26) having significantly less favourable
prognosis than patients scoring between 0.25 and 0.75 (-O-, n = 80) as well as patients scoring below 0.25 (-A-, n = 15).
(P<0.0001 product limit, Mantel-Cox). f, Patients with prognostic three-variable score at or above 0.75 (-A-, n = 12) having
significantly less favourable prognosis than patients scoring between 0.25 and 0.75 (-O-, n = 80) as well as patients scoring below
0.25 (-A-, n=25). (P<0.0001 product limit, Mantel-Cox).
0.05 log rank) (Figure 1). The S-phase fraction (SPF) alone
was not a significant prognostic factor, but when the
imbalance between different DNA ploidies' SPF was cont-
rolled for by adjusting the individual SPF with respect to the
median SPF ofeach respective DNA ploidy group SPF index
was also a highly significant prognostic factor. Patients with
SPF above the median had a median survival of only 16
months (95% confidence 12-25) compared with 36 months
(95% confidence 21-43) among low-SPF patients. The differ-
ence is highly significant (P<0.002, log rank test) (Figure 1).
Multivariate analysis
Age, TNM stage, DNA ploidy, SPF index and relative
growth rate were entered as covariates in Cox's multivariate
analysis. SPF above the median was the most important
determinant of poor prognosis (P<0.002), followed by
DNA diploidy (P<0.05) and TNM stage IV (P>0.05)
(Figure 1), and high relative growth rate under mouse renal
capsule (P>0.05).
Prognostic scoring system
We developed a prognostic scoring system combining the
results of DNA flow cytometry and tumour growth rate with
the clinical TNM stage of the tumour. A patient scored 1
point for each of the following features: SPF above respec-
tive ploidy group median, TNM stage IV, DNA diploidy,
and relative growth rate above the median. The crude score
obtained is then divided by the number of parameters avail-
able for that individual patient. The resulting score ranges
from 0 to 1. In a patient scoring 0 all the observed para-
meters indicate favourable prognosis, and in a patient scoring
1 all the parameters indicate unfavourable prognosis.
The score is a highly significant prognostic tool in the Cox
model (P<0.0001). Patients scoring at or above 0.75 have a
median survival of 11 months (95% confidence 6-13) com-
pared with 29 months (95% confidence 16-?) among patients
scoring below 0.25 (Figure 1).
If the data on growth rate are omitted, and the scoring is
based solely on DNA flow cytometry parameters and clinical
TNM stage, the scoring separates subpopulations with an
even more different prognosis (Table II, Figure 1).
Discussion
In the present study we analysed 117 melanoma patients'
metastases with DNA flow cytometry and determined the
growth rate of the tumours in vivo under the mouse renal
capsule. The observations were correlated with the clinical
outcome of these patients. We also propose an efficient scor-
ing method for determining the prognosis of metastatic
melanoma patients.
In our previous study on basically the same patient popu-
lation we observed that DNA aneuploid metastatic mela-
noma patients exhibited a more favourable prognosis than
did DNA diploid patients (Muhonen et al., 1991). This
observation is in contrast to most of the studies on primary
melanoma, where diploidy is associated with better prognosis
(Bartkowiak et al., 1991; Biichner et al., 1985; Frankfurt et
al., 1984; Kheir et al., 1988; Lindholm et al., 1989; S0nder-
gaard et al., 1983; von Roenn et al., 1986). Significance of
aneuploidy as an independent adverse prognostic sign has,PROGNOSTIC FACTORS IN METASTATIC MELANOMA 531
Table II Relationship ofDNA flowcytometric and clinical parameters to survival after
first melanoma metastases using Brookmeyer-Crawley 95% confidence limits formedian
survival and product limit Mantel-Cox test for survival analysis
n Median 95% Observedl
survival confidence expected x2 p
DNA ploidy
Diploid 41 16 13-25 1.29
Aneuploid 73 27 23-36 0.88 2.65 >0.05
SPF index
Above median 45 16 12-25 1.53
At or below median 46 36 22-43 0.70 10.4 0.0013
Tumour growth rate
Above median 41 22 15-35 1.16
At or below median 41 31 25-39 0.87 1.3 >0.05
Stage at relapse
III 58 27 25-37 0.73
IV 59 13 11-27 1.38 8.35 0.0038
Sex
Female 49 25 15-35 0.98
Male 68 25 16-31 1.01 0.01 >0.05
Score (3 parameters)
<0.25 25 35 23- 0.63
0.25-0.75 80 26 18-31 1.02
>0.75 12 6 5-11 4.46 32.02 <0.0001
Score (4 parameters)
<0.25 15 29 16- 0.59
0.25-0.75 76 31 25-37 0.86
>0.75 26 11 6-13 2.43 23.37 <0.0001
however, been challenged in the latest reports (Gattuso et al.,
1990; Rode et al., 1991). In contrast to the present study of
metastases, all but one (S0ndergaard et al., 1983) of the
studies reporting poor prognosis of aneuploid tumours have
been done on primary lesions. Since the primary operation as
well as the histopathological diagnosis was performed in
variable institutions, these samples were not accessible for the
present analysis.
Like the DNA ploidy pattern, SPF has been described to
have prognostic value for metastatic melanomas (Hansson et
al., 1982; Muhonen et al., 1991). In the present study, low
SPF was observed to be an indicator of a good prognosis.
This was seen only after stratification by ploidy. DNA dip-
loid tumours had in general lower SPF values, but less
favourable prognosis than did DNA aneuploid tumours.
However, within each ploidy group patients with lower SPF
had significantly more favourable prognosis.
The clinical relevance of subrenal capsule assay is contro-
versial. In studies on non-small cell lung carcinomas (Tueni
et al., 1987) and on colorectal carcinoma (Kouri et al., 1989)
a high proportion of the tumour specimens contained no
viable tumour cells after the 6 day assay despite the fact that
they were optically measured to have grown under the renal
capsule during the assay. In contrast, in the study by
Dumont and coworkers all the melanoma specimens in the
control group were confirmed to contain tumour cells at the
end of the 6-day assay (Dumont et al., 1984).
Another source of uncertainty is that the DNA ploidy of
samples taken from different areas of a tumour varies con-
siderably (Fuhr et al., 1991; Kallioniemi, 1988; S0rensen et
al., 1990). Thus the piece of tumour placed under the renal
capsule may actually represent only a diploid clone, although
a larger specimen of the same tumour analysed by DNA flow
cytometry also shows an aneuploid clone in addition to the
diploid clone.
In addition, the S-phase fraction varies considerably in
different samples of the same tumour (Kallioniemi, 1988).
This could in part explain the observed lack of correlation
between the SPF and growth rate. One has to bear in mind
that SPF does not directly indicate the growth rate of the
tumour, but merely indicates the proportion of cells syn-
thesising DNA. Thus the potential doubling based on BRDU
labelling might correlate more clearly with growth rate.
Unfortunately BRDU labelling results are available for only
a minority of our patients.
Mouse subrenal capsule assay has been generally used for
determining the chemosensitivity of a tumour, but not for
determining the prognosis of the patient (Bogden et al., 1978;
Maenpaa, 1985). Despite this, it is theoretically reasonable to
expect that tumours that grow quickly under the mouse
kidney capsule would also grow aggressively in vivo. Not
surprisingly, in our patient population a markedly high
growth rate was clearly associated with unfavourable prog-
nosis.
The reason for the increase in growth rate in consecutive
series remains unclear. No conscious modifications in the
methodology have been performed. The handling of the
tumour specimen may, however, have improved over the
years, resulting in more nearly optimal growth conditions of
the tumour specimen.
As a result of multivariate analysis we propose a simple
but effective prognostic scoring method, which combines the
results of DNA flow cytometry and tumour growth rate with
TNM stage. Because all the parameters are not necessary for
scoring, patients for whom growth rate data is missing for
example can be scored and compared with cases with com-
plete data. DNA flow cytometry is today available in most
pathological units as a routine method, but for routine
clinical use the scoring might be more easily applicable when
the labour consuming in vivo growth rate analysis is omitted.
Similar approaches combining FCM and other prognostic
parameters have been reported in oropharyngeal squamous
epithelium carcinomas (Feichter et al., 1987), soft tissue sar-
comas (Alvegard et al., 1991; Bauer et al., 1991), squamous
cell carcinoma of cervix uteri (Jacobsen et al., 1985) and
breast carcinoma (Sigurdsson et al., 1990; van der Linden et
al., 1989) but not in melanoma. Indeed, there are few para-
meters with any prognostic value in metastatic melanoma. In
the large studies by Balch and colleagues (Balch et al., 1981;
Balch et al., 1985) the only parameters that significantly
predicted the survival after the appearance of lymph node
metastases were (1) number of affected nodes (2) ulceration
of the primary lesion, and after the appearance of distant
metastases were (1) the number of metastatic sites, (2) the532 T. MUHONEN et al.
sites of metastases, and (3) the remission duration.
Since the survival of a melanoma patient with metastases
clearly depends on multiple prognostic factors, it seems irra-
tional to use for prognostic purposes only one or few para-
meters. A complete estimate of the malignant potential ofthe
metastasis can be achieved only by combining all the factors
affecting the course of the disease. Our prognostic score aims
in this direction. The high sensibility of the scoring and the
flexibility in the parameters necessary make it easily app-
licable to routine oncology.
The authors want to thank medical laboratory technologists Paivi
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